• Drug: Linzess (linaclotide)
  • Manufacturer: AbbVie | Ironwood Pharmaceuticals

  • Route of Administration: Oral

  • Site of Care: Outpatient

  • Approved Indication:

    • treatment of irritable bowel syndrome with constipation in adults
    • treatment of chronic idiopathic constipation in adults
    • treatment of functional constipation in pediatric patients 6 to 17 years of age

  • Disease: irritable bowel syndrome with constipation (IBS-C), chronic idiopathic constipation (CIC), functional constipation

  • Therapeutic Area: Gastroenterology

  • Enrollment Form Link: N/A
  • Phone Number: N/A
  • Fax Number: N/A
  • Product Website: linzess.com